Skip to content

Vomiting on Wegovy, Zepbound, Ozempic and other GLP-1 medicines

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Ozempic vomiting is in the label's table: 5% to 9.2% of adults, against 2.3% on placebo. All eight GLP-1 labels list vomiting. In adult trials it was reported by 24% on Wegovy 2.4 mg (6% on placebo) and 8% to 13% on Zepbound (2%). The labels warn that dehydration from vomiting has led to acute kidney injury, so tell your prescriber if you can't keep fluids down.

Key takeaways

  • All eight GLP-1 labels list vomiting, and several tie it to the weeks when the dose is being raised.
  • Report vomiting that repeats, stops you keeping fluids down, or follows each dose increase.
  • Dehydration from vomiting has led to acute kidney injury, in some cases requiring hemodialysis.
  • Vomiting with severe or persistent abdominal pain needs prompt medical attention. Call 911 if you believe it's an emergency.
  • Don't skip or change a dose on your own. Your prescriber decides whether a dose step should wait.

How often it was reported in the label's trials

Zepbound: Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2) · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
ReactionPlacebon=9585 mgn=63010 mgn=94815 mgn=941
Vomiting2%8%11%13%

FDA label: Zepbound, Revised: 8/2026 (DailyMed version 40)

Mounjaro: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in ≥5% of MOUNJARO-treated Adult Patients with Type 2 Diabetes Mellitus · Pool of two placebo-controlled trials in adults with type 2 diabetes (SURPASS-1 monotherapy and SURPASS-5 added to basal insulin with or without metformin); 718 patients exposed to Mounjaro for a mean of 36.6 weeks. Hypoglycemia is not included.
ReactionPlacebon=2355 mgn=23710 mgn=24015 mgn=241
Vomiting2%5%5%9%

FDA label: Mounjaro, Revised: 8/2026 (DailyMed version 40)

Wegovy: Table 3. Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY 2.4 mg Injection-treated Adults with Obesity or Overweight for Weight Reduction · Adults with obesity or overweight in 3 randomized, double-blind, placebo-controlled trials, treated with Wegovy 2.4 mg injection for up to 68 weeks plus a 7-week off-drug follow-up. The label shows '<1' for placebo eructation. The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 3: Wegovy N=403, placebo N=402). Abdominal pain, fatigue, gastritis and dysesthesia are grouped terms.
ReactionPlacebon=1261Wegovy injection 2.4 mg once weeklyn=2116
Vomiting6%24%
Wegovy: Table 4. Adverse Reactions (2% and Greater Than WEGOVY 2.4 mg and Placebo) in WEGOVY 7.2 mg Injection-treated Adults with Obesity for Weight Reduction · Adults with obesity (BMI of 30 or more) in two 72-week, double-blind, randomized, placebo-controlled, 3-armed trials (Study 8 and Study 9, the second in patients with type 2 diabetes). Dysesthesia, abdominal pain, fatigue and dizziness are grouped terms.
ReactionPlacebon=303Wegovy injection 2.4 mg once weeklyn=304Wegovy injection 7.2 mg once weeklyn=1311
Vomiting6%16%22%
Wegovy: Table 5. Adverse Reactions (≥3% and Greater than Placebo) in WEGOVY 2.4 mg Injection-treated Pediatric Patients Aged 12 Years and Older with Obesity for Weight Reduction · Pediatric patients aged 12 years and older with obesity in a 68-week, double-blind, randomized, placebo-controlled trial of Wegovy 2.4 mg injection.
ReactionPlacebon=67Wegovy injection 2.4 mg once weeklyn=133
Vomiting10%36%

FDA label: Wegovy, Revised: 6/2026 (DailyMed version 19)

Ozempic: Table 1. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of OZEMPIC-Treated Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in 2 placebo-controlled trials (1 monotherapy trial and 1 trial in combination with basal insulin); mean duration of exposure to Ozempic was 32.9 weeks. The table excludes hypoglycemia.
ReactionPlacebon=262Ozempic 0.5 mgn=260Ozempic 1 mgn=261
Vomiting2.3%5%9.2%

FDA label: Ozempic, Revised: 5/2026 (DailyMed version 20)

Foundayo: Table 1: Adverse Reactions Reported in ≥5% of FOUNDAYO-treated Adult Patients with Obesity or Overweight (With or Without Type 2 Diabetes) in Pool of Placebo-Controlled Trials (Trials 1 and 2) · Pool of two randomized, double-blind, placebo-controlled weight management trials (Trials 1 and 2) that included 3155 adults with obesity or overweight, with or without type 2 diabetes, treated with Foundayo once daily for up to 72 weeks plus a 2-week off-drug follow-up period.
ReactionPlacebon=15765.5 mgn=10519 mgn=105517.2 mgn=1049
Vomiting4%13%21%24%

FDA label: Foundayo, Revised: 7/2026 (DailyMed version 10)

Rybelsus: Table 2. Adverse Reactions in Placebo-Controlled Trials Reported in ≥5% of Semaglutide Tablets-Treated Patients with Type 2 Diabetes Mellitus · Adults with type 2 diabetes in 2 placebo-controlled trials of semaglutide tablets (Rybelsus); mean duration of exposure was 41.8 weeks. The table excludes hypoglycemia.
ReactionPlacebon=362Semaglutide tablets 7 mgn=356Semaglutide tablets 14 mgn=356
Vomiting3%6%8%

FDA label: Rybelsus, Revised: 1/2026 (DailyMed version 14)

Saxenda: Table 2. Adverse Reactions Occurring in ≥2% of SAXENDA-treated Adult Patients and More Frequently than Placebo · Adults with overweight or obesity in 5 double-blind, placebo-controlled trials, treated for up to 56 weeks (3 trials), 52 weeks (1 trial) and 32 weeks (1 trial). The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 2: Saxenda N=423, placebo N=212), defined as blood glucose below 54 mg/dL with or without symptoms.
ReactionPlacebon=1941Saxendan=3384
Vomiting3.9%15.7%
Saxenda: Table 3. Adverse Reactions Occurring in ≥3% of SAXENDA-treated Pediatric Patients and More Frequently than Placebo in a 56 Week Clinical Trial · Pediatric patients aged 12 years and older with obesity, without type 2 diabetes, in a 56-week placebo-controlled trial. The hypoglycemia row is defined as blood glucose below 70 mg/dL with symptoms.
ReactionPlacebon=126Saxendan=125
Vomiting4%34.4%

FDA label: Saxenda, Revised: 6/2026 (DailyMed version 22)

Trulicity: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials That Occurred in ≥5% of TRULICITY-Treated Adult Patients with Type 2 Diabetes Mellitus · Pool of placebo-controlled trials that included 1,670 adults with type 2 diabetes exposed to Trulicity 0.75 mg or 1.5 mg, with a mean duration of exposure of 23.8 weeks. Hypoglycemia is excluded.
ReactionPlacebon=5680.75 mgn=8361.5 mgn=834
Vomiting2.3%6%12.7%
Trulicity: Table 2: Adverse Reactions That Occurred in ≥5% of TRULICITY-treated Adult Patients with Type 2 Diabetes Mellitus in a Clinical Trial through 36 Weeks · Clinical trial of 1842 adults with type 2 diabetes treated with Trulicity 1.5 mg, 3 mg, or 4.5 mg once weekly as add-on to metformin, through 36 weeks (no placebo arm).
Reaction1.5 mgn=6123 mgn=6164.5 mgn=614
Vomiting5.6%8.3%9.3%

FDA label: Trulicity, Revised: 3/2026 (DailyMed version 62)

Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.

If you’re vomiting on a GLP-1 medicine, tell your prescriber if it repeats, if it stops you keeping fluids down, or if it follows each dose increase. If it comes with severe or persistent abdominal pain, contact a doctor promptly, and call 911 if you believe it’s an emergency.

Vomiting is reported less often than nausea in every label table, but it’s the reaction the labels’ kidney warning is most concerned with. The tables on this page give the full figures.

What the labels report

Each figure is the share of trial patients who reported vomiting, next to the placebo group from the same trials. A placebo group gets an inactive treatment instead of the medicine.

Adults, weight management trials

  • Wegovy 2.4 mg injection (three trials): 24%, with 6% on placebo. In the 7.2 mg trials: 22% on 7.2 mg, 16% on 2.4 mg and 6% on placebo.
  • Foundayo (two pooled trials): 13% at 5.5 mg, 21% at 9 mg and 24% at 17.2 mg, with 4% on placebo.
  • Saxenda (five trials): 15.7%, with 3.9% on placebo.
  • Zepbound (two pooled trials): 8% at 5 mg, 11% at 10 mg and 13% at 15 mg, with 2% on placebo.

Adults, type 2 diabetes trials

  • Trulicity (pooled trials): 6.0% at 0.75 mg and 12.7% at 1.5 mg, with 2.3% on placebo. In its higher-dose trial, with no placebo arm: 5.6% at 1.5 mg, 8.3% at 3 mg and 9.3% at 4.5 mg.
  • Ozempic injection (two trials): 5% at 0.5 mg and 9.2% at 1 mg, with 2.3% on placebo.
  • Mounjaro (two pooled trials): 5% at 5 mg, 5% at 10 mg and 9% at 15 mg, with 2% on placebo. In its cardiovascular outcomes trial, the label reports vomiting in 12% of patients on Mounjaro.
  • Rybelsus (two trials; the label also covers Ozempic tablets): 6% at 7 mg and 8% at 14 mg, with 3% on placebo.

Children and adolescents

  • Wegovy 2.4 mg, aged 12 and older with obesity: 36%, with 10% on placebo.
  • Saxenda, aged 12 and older with obesity: 34.4%, with 4% on placebo.
  • Mounjaro, aged 10 and older with type 2 diabetes (30-week trial): 16% at 5 mg and 12% at 10 mg, with 3% on placebo.

These trials were run separately, in different groups of people. So the figures describe each medicine against its own placebo group and nothing more.

When does vomiting happen?

The labels place it in the weeks when the dose is being raised, which they call dose escalation. Zepbound’s says most nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. Foundayo’s says the incidence was higher during dosage escalation and decreased over time. The Ozempic and Rybelsus labels say the majority of reports occurred during dose escalation, and Wegovy’s says gastrointestinal (stomach and bowel) reactions were most frequently reported then.

Vomiting was also one of the reactions that led people to stop. In the adult Wegovy 2.4 mg trials, 1.2% of patients stopped permanently because of vomiting, against 0% on placebo. In the adult Saxenda trials it was 1.7%, against less than 0.1%.

The kidney warning

Every one of the eight labels has a warning titled “Acute Kidney Injury Due to Volume Depletion.” Volume depletion means losing too much fluid. Trulicity’s wording is typical. There have been postmarketing reports (reports made after approval) of acute kidney injury, “in some cases requiring hemodialysis,” a treatment in which a machine filters the blood, and “the majority of the reported events occurred in patients who experienced gastrointestinal reactions leading to dehydration such as nausea, vomiting, or diarrhea.”

The Wegovy label gives trial numbers as a rate. Acute kidney injury occurred in 7 adults on Wegovy (0.4 cases per 100 patient years) and 4 on placebo (0.2 cases per 100 patient years) in the weight reduction trials. The label then tells prescribers to monitor kidney function in patients reporting reactions that could lead to volume depletion, especially while the dose is being started and raised.

Vomiting with abdominal pain

The pancreatitis warnings on the Wegovy, Ozempic and Saxenda labels describe the signs as persistent or severe abdominal pain, sometimes radiating to the back, “which may or may not be accompanied by nausea or vomiting.” Pancreatitis is an inflammation of the pancreas. The labels say the medicine should be discontinued if pancreatitis is suspected. That’s a judgment for a clinician who has examined you, which is why this combination calls for prompt medical attention. There’s more on our abdominal pain page.

When to contact your prescriber

Report vomiting that repeats, that stops you keeping fluids down, or that follows each dose increase. Your prescriber decides whether a dose step should wait. Don’t skip or change a dose on your own. If vomiting comes with severe or persistent abdominal pain, contact a doctor promptly, and call 911 if you believe it’s an emergency.

One more possibility is worth ruling out. If vomiting began after a dose you measured yourself from a vial, the dosing error checker explains how unit mix-ups happen.

Related pages: nausea, diarrhea and the side effects overview.

Frequently asked questions

Is vomiting a common side effect of Ozempic?

Yes, it's in the Ozempic injection label's table of common reactions. In two placebo-controlled trials in adults with type 2 diabetes, 5% of patients on 0.5 mg and 9.2% on 1 mg reported vomiting, compared with 2.3% on placebo. The label says most reports of nausea, vomiting and diarrhea came during dose escalation, the weeks when the dose is being raised.

Does vomiting increase with the dose?

In most of the label tables, the groups on higher doses report more vomiting. Zepbound shows 8% at 5 mg, 11% at 10 mg and 13% at 15 mg. Foundayo shows 13%, 21% and 24% across its three dose groups. Trulicity shows 6.0% at 0.75 mg and 12.7% at 1.5 mg. These come from separate trials, so they don't compare one medicine with another.

Is vomiting more common in teenagers on Wegovy or Saxenda?

The adolescent trials report higher figures than the adult ones. In patients aged 12 and older with obesity, 36% on Wegovy 2.4 mg reported vomiting against 10% on placebo, and 34.4% on Saxenda against 4% on placebo. The adult figures were 24% for Wegovy 2.4 mg and 15.7% for Saxenda.

When is vomiting on a GLP-1 an emergency?

The labels flag two situations. Vomiting that leaves you dehydrated matters because dehydration has led to acute kidney injury, in some cases requiring hemodialysis. Vomiting with persistent or severe abdominal pain matters because the labels describe that pain as a sign of acute pancreatitis. Contact a doctor promptly in either case, and call 911 if you think it's an emergency.

Sources (8)

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.